

February 27, 2015

ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
Public_relations@ono.co.jp

Amgen Announces Results from Phase 3 Clinical Study
Comparing AMG 416/ONO-5163 with Cinacalcet Hydrochloride
for the Treatment of Patients with Secondary Hyperparathyroidism

On February 25, 2015 (PST), Amgen announced results from a Phase 3 clinical study comparing AMG 416 with cinacalcet hydrochloride for the treatment of secondary hyperparathyroidism patients with chronic kidney disease receiving hemodialysis.

The study met the primary endpoint of non-inferiority of AMG 416 compared to cinacalcet, measured as the achievement of a greater than 30 percent reduction from baseline in serum intact parathyroid hormone (PTH) levels.

For your further information, visit the link below to the website for press release distributed by Amgen.

http://wwwext.amgen.com/media/media_pr_detail.jsp?releaseID=2020209

In Japan, ONO is currently conducting a clinical study in patients with secondary hyperparathyroidism in accordance with the license agreement* concluded with Amgen, formerly KAI Pharmaceuticals in September 2011.

* In Japan, ONO has exclusive rights to develop and commercialize the agonist of calcium sensing receptor (AMG 416/ONO-5163), which Amgen is currently developing.